Visual Field Test for Glaucoma: How It Works

The test relies on a straightforward principle: measuring your ability to detect small points of light presented at various locations across your visual field.

During standard automated perimetry, a computer-controlled instrument projects brief flashes of light at different brightness levels and positions inside a dome-shaped bowl. Each time you notice a flash, you press a button. The machine records which lights you saw and which you missed, then generates a detailed map of your visual sensitivity. This method is highly reliable because the computer adjusts the brightness of each flash based on your responses, pinpointing the exact threshold at which you can detect light in each area.

A threshold test measures the dimmest light you can see at many individual points, providing detailed information about the depth and extent of any vision loss. A screening test, by contrast, simply checks whether you can see a light at a set brightness level at each location. Threshold testing is the standard for glaucoma monitoring because it offers more precise data. Screening tests are typically reserved for initial evaluations or large-scale population screenings.

Most glaucoma evaluations use a central 24-2 or 30-2 test pattern, which measures the central 24 or 30 degrees of your visual field. The 24-2 pattern is the most widely used because it covers the area where glaucoma-related peripheral vision loss typically appears first. In some cases, a 10-2 pattern may be used to evaluate central vision in more advanced glaucoma.

Your results are displayed as a series of maps and numerical charts that show how sensitive each part of your visual field is to light. Areas of reduced sensitivity appear as darker regions on the grayscale map, while the pattern deviation plot highlights areas of loss that stand out compared to age-matched normal values. Your doctor also reviews reliability indices, such as fixation losses and false positive rates, to confirm the test was performed accurately. You can learn more about reading your OCT scan and visual field results to better understand your report.

Most glaucoma patients benefit from visual field testing at least once or twice per year. Newly diagnosed patients or those with signs of progression may be tested more frequently, sometimes every three to four months, to establish a reliable baseline. Once your condition is stable and a strong treatment response has been confirmed, your doctor may reduce the frequency to annual testing.

There is no pass or fail outcome on a visual field test. The test simply measures your current visual function at that moment. However, an unreliable test, one with too many fixation losses, false positives, or false negatives, may not provide useful clinical information. When this happens, your doctor may ask you to repeat the test at a future visit. Fatigue, inattention, and a steep learning curve during your first few tests are the most common reasons for unreliable results.

Glaucoma produces distinctive patterns of vision loss that correspond to the anatomy of the optic nerve. An arcuate scotoma, a curved band of vision loss arching above or below the center of your visual field, is one of the hallmark findings. A nasal step, where the upper and lower halves of the nasal field do not align, is another classic pattern. In early glaucoma, you may see isolated clusters of depressed points called paracentral scotomas. These patterns help distinguish glaucoma from other conditions that affect the visual field differently.

By comparing your visual field results over time, your doctor can detect whether areas of loss are deepening or expanding. Software built into the perimetry instrument, such as Guided Progression Analysis (GPA), uses statistical methods to flag points that are worsening beyond normal test-to-test variability. This longitudinal tracking is one of the primary ways we determine whether your current glaucoma treatment plan needs to be adjusted to better protect your remaining vision.

The visual field test is painless and non-invasive. You will not feel anything touching your eye, and no drops or injections are involved. Some patients find the test mildly tiring, particularly toward the end, because sustained concentration in a dimly lit room can be fatiguing. Taking a brief pause mid-test and remembering to blink regularly can help. Most patients describe the experience as easy and straightforward once they have completed it a few times.